Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Join us on Tuesday 13th September 2022 to hear about the challenges and Oxford-based opportunities in early cancer detection, and how you can apply your research to this burgeoning field.

OxCODE logo

We are delighted to have Professor Peter Sasieni as our keynote speaker (Director, King's College London Clinical Trials Unit).

There will be other sessions themed on:

  • Challenges in early cancer detection, featuring Ellie Barnes, James East, Bethan Psaila and Alexis Webb (Research Programme Manager for Early Detection, Cancer Research UK)
  • Oxford-based opportunities for early detection, featuring Daniel Anthony, Sarah Blagden, Martin Booth, Brian Nicholson, Jens Rittscher and Daniel Royston
  • Opportunities for patient input, featuring Tom Doust (Oxford Cancer PPI group member), Catriona Gilmour Hamilton (Patient Experience and Engagement, Oxford University Hospitals NHS Trust) and Julliet Lwiindi (Oxford Cancer PPIE officer)

The Symposium will also feature lightning talks, an early cancer detection poster session (abstract submission deadline, 25th August*), and a drinks and canapés networking reception.

This free event is for members of Oxford University and OUHFT only.

Register here by 25th August.


Please contact with any questions.

Similar Stories

First patient diagnosed earlier using liquid biopsy technology as part of the AI-REAL programme in sub-Saharan Africa

The AI-REAL programme led by Professor Anna Schuh and research teams in Tanzania and Uganda is improving the early detection and outcomes of childhood lymphoma in the region by increasing the speed and precision of diagnosis.

Measured weight loss associates with an increased risk of a cancer diagnosis

Weight loss is a sign of undiagnosed cancer regardless of the interval over which it occurs.

Comparing polygenic risk scores for risk prediction in individuals

Substantial disagreement in individual risk prediction was found between different polygenic risk scores for breast cancer, hypertension and dementia using genotyping data from the UK Biobank.